双刺激反应性肠道微生物群向尼提丁化物-CS/PT-NP 改善了NAFLD中的代谢状态
Jianmei Lu1,2, Yongzhu Zeng1, Huashuai Zhong1
1Department of Pharmacy, Guangxi Medical University, Nanning, People's Republic of China.
International journal of nanomedicine
|March 13, 2024
概括
这项研究开发了针对结肠的纳米粒子 (NC-CS/PT-NP),通过调节肠道微生物群来治疗非酒精性脂肪性肝病 (NAFLD). 这些纳米颗粒有效地将尼提丁化物 (NC) 输送到结肠,改善肝脏健康并改变小鼠的肠道细菌.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 胃肠病学和肝病学
- 微生物学 微生物学
背景情况:
- 尼提丁化物 (NC) 具有抗炎和抗癌特性,但溶性不佳.
- 非酒精性脂肪肝 (NAFLD) 是一个日益严重的健康问题,通常与肠道失调有关.
- 开发有效的治疗化合物输送系统对于治疗肝脏疾病至关重要.
研究的目的:
- 为尼提丁化物 (NC) 创建一个针对结肠的输送系统 (NC-CS/PT-NP).
- 通过调节肠道微生物群来研究NC-CS/PT-NP在治疗非酒精性脂肪性肝病 (NAFLD) 的疗效.
- 加强NC和肠道微生物群之间的相互作用,以改善治疗结果.
主要方法:
- 使用离子凝方法合成NC-CS/PT-NP.
- 纳米粒子属性的表征,包括大小,形态,药物加载和释放动力学.
- 在高脂肪饮食诱导的NAFLD小鼠体内评估,包括生物化学分析,ELISA,组织化学和16S rDNA基因测序用于肠道微生物群分析.
主要成果:
- NC-CS/PT-NPs在结肠中表现出受控释放 (66.75%),在胃和小肠中释放最小.
- 在体内研究表明,在NAFLD小鼠中抑制体重增加,降低肝酶 (AST,ALT) 和脂质,改善肝/肠炎症.
- 治疗显著改变了HFD诱导的NAFLD小鼠的肠道微生物群多样性.
结论:
- 针对结肠的NC-CS/PT-NP有效地改善了小鼠的NAFLD.
- 通过NC-CS/PT-NP调节肠道微生物群,在治疗NAFLD方面发挥着关键作用.
- 这种方法突显了传统中医药活性成分与肝病治疗的先进输送系统相结合的潜力.
更多相关视频
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
01:17Drugs for Treatment of Diarrhea-Predominant IBS
167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331